Review Article
A Review of Current Trends and Advances in Analytical Methods for Determination of ACE Inhibitors Combinations with Hydrochlorothiazide
Issue:
Volume 11, Issue 2, June 2025
Pages:
13-30
Received:
31 January 2025
Accepted:
28 February 2025
Published:
24 May 2025
Abstract: Background. Hypertension is a leading risk factor for cardiovascular diseases, contributing significantly to global morbidity and mortality. Combination therapy using an angiotensin-converting enzyme (ACE) inhibitor with a diuretic offers distinct advantages over monotherapy in managing hypertension. With the increasing use of fixed-dose combination therapies, there is a growing demand for analytical methods that can accurately, precisely, and cost-effectively assess these complex formulations. Objective. This review examines the various analytical methods used to analyze ACE inhibitor combinations with hydrochlorothiazide, focusing on studies published between 1990 and 2024. The methods are critically evaluated, compared, and assessed for their practical applicability. Results. A review of the literature revealed that different analytical techniques have been employed for the determination of ACE inhibitor–hydrochlorothiazide combinations. Recent trends indicate a preference for HPLC (48.7%), spectrophotometric methods (23.1%), thin-layer chromatography (TLC) (15.4%), capillary electrophoresis (7.7%), and Fourier transform infrared (FTIR) spectroscopy (5.1%). Conclusion and main ideas. HPLC remains the gold standard for the analysis of ACE inhibitor–hydrochlorothiazide combinations. However, alternative methods like spectrophotometry and TLC provide viable options for simpler and cost-effective analysis The selection of an appropriate analytical technique should align with analytical goals, regulatory compliance, and available resources. Future research may focus on advancing rapid and environmentally friendly analytical techniques.
Abstract: Background. Hypertension is a leading risk factor for cardiovascular diseases, contributing significantly to global morbidity and mortality. Combination therapy using an angiotensin-converting enzyme (ACE) inhibitor with a diuretic offers distinct advantages over monotherapy in managing hypertension. With the increasing use of fixed-dose combinatio...
Show More
Research Article
Computational Insights into the Antimalarial Potential of Geranylated Chalcone from Terminalia brownii: A Multi-target Approach Against Plasmodium Falciparum Enzymes
Issue:
Volume 11, Issue 2, June 2025
Pages:
31-38
Received:
17 June 2025
Accepted:
14 July 2025
Published:
30 July 2025
DOI:
10.11648/j.jddmc.20251102.12
Downloads:
Views:
Abstract: The emergence of resistance to existing antimalarial therapies has escalated the urgency for novel compounds that effectively inhibit Plasmodium falciparum. This comprehensive study explores the antimalarial potential of Geranylated Chalcone, a bioactive compound extracted from Terminalia brownii. The molecular structure of Geranylated Chalcone was generated and optimized using ChemDraw and Spartan14 software, respectively, and evaluated its theoretical bioavailability and toxicity profiles through the SwissADME web platform and ProTox 3.0 tool. Molecular docking studies was performed with AutoDock Vina to assess binding interactions with critical enzymes, including Falcipain-2, Falcipain-3, Plasmepsin-2, and Aminopeptidase. Geranylated Chalcone displayed notable binding affinities ranging from -6.4 to -7.3 kcal/mol, indicating substantial interactions facilitated by hydrogen bonds, van der Waals forces, and pi interactions. Furthermore, the compound demonstrated a favorable drug-likeness profile, adhering to Lipinski's rule of five and exhibiting low toxicity (LD50: 2652mg/kg). These findings substantiate that Geranylated Chalcone serves as a promising candidate for antimalarial drug development, possessing advantageous binding affinities and a multi-target profile. Elucidation of its therapeutic efficacy, in vitro and in vivo studies are essential to validate its potentiality as a groundbreaking antimalarial agent. This research contributes valuable insights into the multifaceted role of natural compounds in combating malaria and the pressing challenge of drug resistance.
Abstract: The emergence of resistance to existing antimalarial therapies has escalated the urgency for novel compounds that effectively inhibit Plasmodium falciparum. This comprehensive study explores the antimalarial potential of Geranylated Chalcone, a bioactive compound extracted from Terminalia brownii. The molecular structure of Geranylated Chalcone was...
Show More